Skip to content

The effect of supraglottic jet ventilation on patient's ventilation distribution during painless bronchoscopy: an observational study using electrical impedance tomography

The effect of supraglottic jet ventilation on patient's ventilation distribution during painless bronchoscopy: an observational study using electrical impedance tomography

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050285
Enrollment
Unknown
Registered
2021-08-25
Start date
2021-08-23
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchoscopy diagnosis and treatment

Interventions

Case series:supraglottic jet ventilation through a nasopharyngeal airway

Sponsors

Shanghai Pulmonary Hospital, Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients plan to undergo painless bronchoscopy; 2.Aged >= 18 years; 3.ASA I~III; 4.Have completed relevant ancillary tests, such as routine blood, pulmonary function, liver and kidney function, and blood clotting function, etc.; 5.Patients have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Heart failure NYHA class 3 to 4, pulmonary heart disease CCS class 3 to 4; 2.OSAHS, COPD GOLD grade III-IV, pulmonary fibrosis, evidence of pulmonary alveoli, emphysema, pneumothorax, uncontrolled asthma; 3.End-stage liver disease, end-stage renal disease (GFR <15 ml/min); 4.Decreased basal oxygen saturation (resting SpO2 < 90%), SpO2 < 95% via NC oxygen (4L/min); 5.Basal sinus bradycardia (HR <60 beats/min) with significant bradycardia-related symptoms; 6.Pregnant, lactating women; 7.History of allergy to narcotic drugs, history of drug abuse; 8.History of coagulation disorders, tendency to rhinorrhea, habitual epistaxis, or nasal surgery; 9.A definite infection of the mouth, nose and throat; 10.Pacemakers or implantable cardioverter-defibrillators; 11.Emergency surgery; 12.Patients who are participating in other clinical trials; 13.Otherwise considered by the investigator to be unfit to participate in a clinical trial.

Design outcomes

Primary

MeasureTime frame
Global end-expiratory pulmonary impedance change;Region of interest;

Secondary

MeasureTime frame
Incidence of hypoxemia (SpO2<90%);Intervention measures and frequency of hypoxemia;

Countries

China

Contacts

Public ContactLvy Xin

Shanghai Pulmonary Hospital, Tongji University

xinlvg@126.com+86 13661869972

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026